Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.
about
A Blueprint for HIV Vaccine DiscoveryAntibody responses to envelope glycoproteins in HIV-1 infectionVaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteAntigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsCrystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvA gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionStructural Constraints Determine the Glycosylation of HIV-1 Envelope TrimersCell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 EnvelopeAllosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityA Novel Two-Tag System for Monitoring Transport and Cleavage through the Classical Secretory Pathway - Adaptation to HIV Envelope ProcessingFunctional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)HIV Envelope gp120 Alters T Cell Receptor Mobilization in the Immunological Synapse of Uninfected CD4 T Cells and Augments T Cell ActivationAutoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and MacaquesAntibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralizationThe glycan shield of HIV is predominantly oligomannose independently of production system or viral clade.Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity.Optimized Infectivity of the Cell-Free Single-Cycle Human Immunodeficiency Viruses Type 1 (HIV-1) and Its Restriction by Host Cells.An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cellsMechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein TrimersBinding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virionsTargeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.Discrete partitioning of HIV-1 Env forms revealed by viral capture.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Significant differences in cell-cell fusion and viral entry between strains revealed by scanning mutagenesis of the C-heptad repeat of HIV gp41Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer AntigensProteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibilityNative Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins.Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.Development of prophylactic vaccines against HIV-1.Impact of HIV-1 Membrane Cholesterol on Cell-Independent Lytic Inactivation and Cellular Infectivity.Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.).Antigenic properties of the HIV envelope on virions in solution.Native-like Env trimers as a platform for HIV-1 vaccine design.
P2860
Q26829865-0E87B2A6-959A-45B3-86DC-63073378B3D6Q26991572-D9CDDDB6-5F91-4CC2-8138-1B8DEA346B3DQ27319450-80E649A7-30FB-4BC1-883A-37B0898B9FFCQ27320687-8DCFA7A1-BE9F-4B28-9F2F-BBB79AF2B64BQ27644383-8A59C402-A9FE-4E85-B859-1F90EE0209E1Q27676864-3CABE34D-867B-40DE-812B-69FBA3C3C620Q28263063-8A0F6694-6271-4D15-825A-95EA5BA78C72Q28263655-773410F5-3530-4097-8AD9-06E8CAD2E0ABQ28485983-F5425633-21A8-49F3-9B9F-E5D8B0A0D00DQ28533980-373645F2-EA4F-4C7D-BE39-9E175F45EFE4Q28743199-D8EB120C-873F-491F-8C63-041D2D0402FBQ30828739-06D7A3E0-0BF7-4361-89D4-581BDDB101ACQ33601372-A4346BF8-8D12-4B6D-A607-D23F1BECAFE8Q33683203-0690D852-286F-4DFB-ABA4-B2A88AF9B832Q33946158-1FC1140C-33EF-4C7B-9015-06788F4B9E2DQ33999756-DD256628-7A77-4D93-973C-7859E3BCF8ADQ34034659-54772737-B1EA-4046-9CDD-3439A30F084EQ34172295-49DA5A65-F071-4DBD-9B5A-7741190A3D7DQ34285680-966B0BAB-63BE-49C1-883D-52DFEDFF9B29Q34517381-5393F921-5C6F-4E80-8170-160F2E56A16DQ34611144-E6933F56-C680-42E8-914B-685881F1E067Q34658136-1D170B4F-481D-4698-BDD2-6F06D397C87CQ34794784-F684F545-5994-4E37-A085-AFD18358C794Q34796885-8FCF9711-E800-40E3-A227-DF2397D695E2Q34801630-6DE22C90-5EA2-4942-A200-2930CF4E6F69Q34807480-D2AA0A75-4892-4D23-9695-3F073ABDEBA5Q35689608-C269C701-93B4-4EF1-BB64-3BE354F02D22Q35826171-CF7DA0E8-4C9D-4BF0-8F9A-97CF5266FDADQ36088254-FD317E62-DCA2-48D3-ACC0-517C6A93F6B5Q36303368-C8254CFA-1171-4358-89EB-5A7FAAB5D47FQ36390483-44484A29-F9BA-4FD2-A8B9-57E9683761E1Q36434196-C3EB03A3-A194-4247-AF9F-8AD5572B8FE5Q36559735-322373A8-ED73-4EFC-99FF-39EBD3B17F9FQ36736597-A623D5F0-E475-4451-B4B0-B5AFC1CD564EQ36827300-F97B1017-CE74-4000-887D-62AB2FF3E674Q37042563-4B693C00-F6BD-4DDB-9B7E-62DBDC7D5A07Q37183472-FFA1C3F9-50F3-4954-962C-4F78130EDA90Q37370393-7849C147-DBD3-401D-93F6-598D00981641Q37547245-CC95C299-70E5-4460-9233-29867B8392AAQ37633417-3AB957F7-CF2B-44D4-BDEB-902CBBE867D2
P2860
Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Enzyme digests eliminate nonfu ...... viral infectivity unaffected.
@ast
Enzyme digests eliminate nonfu ...... viral infectivity unaffected.
@en
type
label
Enzyme digests eliminate nonfu ...... viral infectivity unaffected.
@ast
Enzyme digests eliminate nonfu ...... viral infectivity unaffected.
@en
prefLabel
Enzyme digests eliminate nonfu ...... viral infectivity unaffected.
@ast
Enzyme digests eliminate nonfu ...... viral infectivity unaffected.
@en
P2093
P2860
P356
P1433
P1476
Enzyme digests eliminate nonfu ...... viral infectivity unaffected.
@en
P2093
Ema T Crooks
James M Binley
Keiko Osawa
Tommy Tong
P2860
P304
P356
10.1128/JVI.00154-11
P407
P577
2011-04-06T00:00:00Z